Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin vs CNI in Chronic Allograft Nephropathy
NCT00223678Phase 4Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jun 2000
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in Chronic Allograft Kidney Disease (CKaD) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Graft Survival at 3 years. Started Jun 2000; status: completed.
02
Drugs
sirolimus
03
Conditions
Chronic Allograft Kidney Disease (CKaD)
Beyond the preview
Go deeper on NCT00223678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223678.